Zobrazeno 71 - 80
of 99
pro vyhledávání: '"Allison Berger"'
Publikováno v:
Blood. 124:4690-4690
Microenvironment-mediated upregulation of the B-cell receptor (BCR) and nuclear factor-kappaB (NFκB) signaling in the CLL cells resident in the lymph node and bone marrow promotes apoptosis evasion and clonal expansion. We recently reported that str
Autor:
Thomas J. Waldschmidt, Michael R. Acevedo, Van S. Tompkins, Ramakrishna Sompallae, Kaylia Duncan, Alicia K. Olivier, Siegfried Janz, Herbert C. Morse, Guido Tricot, Lorraine T. Tygrett, Susan A. Walsh, Allison Berger, Laura L. Boles Ponto, John Sunderland, Fenghuang Zhan, Timothy R. Rosean
Publikováno v:
Blood Cancer Journal
(18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) and computed tomography (CT) are useful imaging modalities for evaluating tumor progression and treatment responses in genetically engineered mouse models of solid human cancers, but the
Autor:
Min Yang, David Tamang, Simon S. Jones, Steven N. Quayle, Khristofer Garcia, Jeffrey Ciavarri, Jie Yu, Allison Berger, Bret Bannerman
Publikováno v:
Blood. 122:4437-4437
Introduction The combination of HDAC inhibitors and proteasome inhibitors has demonstrated preclinical benefit in several settings, including multiple myeloma and lymphoma, and is being explored in clinical trials testing various HDAC inhibitors in c
Autor:
Michael P. Thomas, Syamala Bandi, Xiaozhen J. Liu, Katherine Cosmopoulos, Eric S. Lightcap, Peter G. Smith, Raymond W. Liu, Khristofer Garcia, Michael D. Pickard, Mike Kuranda, Greg Hather, Allison Berger, David C. Bouck, Jonathan L. Blank
Publikováno v:
Molecular Cancer Therapeutics. 12:B92-B92
MLN4924 is an investigational small molecule inhibitor of the Nedd8-activating enzyme (NAE) currently in Phase 1 clinical trials. MLN4924 induces DNA damage via rereplication in most cell lines. This distinct mechanism of DNA damage may affect its ab
Autor:
Hugues Bernard, James J. Garnsey, Erik Koenig, Ben Amidon, Allison Berger, Eric S. Lightcap, Nibedita Chattopadhyay
Publikováno v:
Molecular Cancer Therapeutics. 12:B156-B156
The investigational proteasome inhibitor ixazomib (MLN2238) inhibits cell growth in a broad panel of solid tumor and hematological cell lines when tested in vitro. In contrast, antitumor activity in xenograft-bearing mice is model-dependent, with som
Autor:
Adrianne L. Stefanski, Tomasz Sosinowski, Virginia D. Winn, Allison Berger, Nathan D. Pennock, Leonard L. Dragone, Lisa K. Peterson, Eric Treacy, Samantha Friend
Publikováno v:
PLoS ONE
PLoS ONE, Vol 8, Iss 10, p e75200 (2013)
PLoS ONE, Vol 8, Iss 10, p e75200 (2013)
While neddylation is known to activate cullin (CUL)-RING ubiquitin ligases (CRLs), its role in regulating T cell signaling is poorly understood. Using the investigational NEDD8 activating enzyme (NAE) inhibitor, MLN4924, we found that neddylation neg
Autor:
Mark R. Conaway, Susan C. Modesitt, Jonghoon Park, Jennifer Bryant, Peter G. Smith, Michael Milhollen, Allison Berger, Amir A. Jazaeri, Anindya Dutta, Etsuko Shibata
Publikováno v:
Cancer Research. 73:3380-3380
Purpose: The objective of this investigation was to evaluate the preclinical activity of MLN4924, an investigational inhibitor of the NEDD8-activating enzyme, against chemoresistant and chemosensitive ovarian cancer cells. ExperimentalDesign: Efficac
Autor:
Juan F. Blanco, Antonio Garcia-Gomez, Jesús F. San-Miguel, Enrique M. Ocio, Allison Berger, Atanasio Pandiella, Laura San-Segundo, Dalia Quwaider, Teresa Paíno, Mercedes Garayoa
Publikováno v:
Blood. 120:4014-4014
Abstract 4014 Introduction: Bone destruction, a hallmark of multiple myeloma (MM), arises as a consequence of the interactions between MM cells and the bone marrow microenvironment, which lead to an increase in the bone-resorptive activity and number
Autor:
N. Chattopadhyay, Paul Hales, Mark Manfredi, J. Garnsey, Allison Berger, E. Koenig, G. Mulligan, Jie Yu, Bret Bannerman, A. DiBacco
Publikováno v:
European Journal of Cancer. 48:69
The investigational drug MLN9708 is a potent, reversible and specific inhibitor of the proteasome. MLN9708 is currently being evaluated in clinical trials of hematologic malignancies (Phase 1, 2, and 3) as well as solid tumors (Phase 1 and 2). Upon e
Autor:
Stephen J. Blakemore, David Smith, Mark G. Qian, John A. Thompson, Gordana Vlahovic, Jeffrey R. Infante, Feng Gao, Raymond W. Liu, Lillian L. Siu, Susan Chen, Doug Bowman, Daniel C. Sullivan, Allison Berger, John S. Kauh, Neeraj Gupta, Alessandra Di Bacco, Bradley Stringer, Stephen Tirrell, Yu Yang, Thea Kalebic
Publikováno v:
Journal of Clinical Oncology. 30:3077-3077
3077 Background: MLN9708 is a potent investigational proteasome inhibitor, which upon intravenous (IV) administration immediately hydrolyzes to the active form MLN2238. MLN9708 is currently being evaluated in a phase 1 trial in solid tumors (NCT00830